AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

BIOPHARMA CREDIT PLC

Director's Dealing Nov 4, 2025

4973_dirs_2025-11-04_a06728a0-ce34-4fa2-8e48-8de9ef18ee1b.html

Director's Dealing

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 1680G

BioPharma Credit PLC

04 November 2025

4 November 2025

BIOPHARMA CREDIT PLC

Notification of Transactions by

Persons Discharging Managerial Responsibilities and

Persons Closely Associated with them

1.

Details of person discharging managerial responsibilities/person closely associated with them

a)

Name

Anita Hyman

2.

Reason for the notification

a)

Position / status

Person Closely Associated with Harry Hyman (Director of BioPharma Credit PLC)

b)

Initial notification / amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

BioPharma Credit PLC

b)

LEI

213800AV55PYXAS7SY24

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification Code

Ordinary Shares of $0.01 each

GB00BDGKMY29

b)

Nature of the transaction

Purchase of Shares (acquired as part of dividend reinvestment)

c)

Price(s) and volume(s)

Price(s) Volume(s)
£0.693518 62

d)

Aggregated information

- Aggregated volume

- Price

N/A

e)

Date of the transaction

03.11.2025

f)

Place of the transaction

London Stock Exchange (XLON)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHBUBDBIDGDGUS

Talk to a Data Expert

Have a question? We'll get back to you promptly.